Evidence map›Paper›PMID 33914276›Full record

ArticlePharmaceutical medicine2021

Symptoms of Medication Withdrawal in Parkinson's Disease: Considerations for Informed Consent in Patient-Oriented Research.

Kaitlyn R Hay, Neevi Kukreti, Paula Trujillo, Ya-Chen Lin, Hakmook Kang, Daniel O Claassen

Abstract read
In one paragraph

Article in Pharmaceutical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kaitlyn R HayDepartment of Neurology, Vanderbilt University Medical Center, 1161 21st Ave South A-0118, Nashville, TN, 37232, USA.ORCID 0000-0003-2143-3932
Neevi KukretiDepartment of Neurology, Vanderbilt University Medical Center, 1161 21st Ave South A-0118, Nashville, TN, 37232, USA.
Paula TrujilloDepartment of Neurology, Vanderbilt University Medical Center, 1161 21st Ave South A-0118, Nashville, TN, 37232, USA.ORCID 0000-0001-9753-7071
Ya-Chen LinDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0003-3660-4570
Hakmook KangDepartment of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.ORCID 0000-0001-6876-4021
Daniel O ClaassenDepartment of Neurology, Vanderbilt University Medical Center, 1161 21st Ave South A-0118, Nashville, TN, 37232, USA. daniel.claassen@vumc.org.ORCID 0000-0002-9853-4902

Funding

Quantitative Imaging of Brain Glymphatic Function in HumansR01AG062574 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CLAASSEN, DANIEL OLIVER, DONAHUE, MANUS J · 2020 to 2024
$3.0M
Biological Determinants of Impulsivity in Parkinson's DiseaseR01NS097783 · NINDS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CLAASSEN, DANIEL OLIVER · 2016 to 2020
$2.2M
Expanding Mentorship and Neuroimaging Expertise in Patient-Oriented Studies of Brain, Behavior, and Age-Related DementiasK24AG064114 · NIA · VANDERBILT UNIVERSITY MEDICAL CENTER · PI CLAASSEN, DANIEL OLIVER · 2020 to 2024
$855k
NIA NIH HHS K24 AG064114NIA NIH HHS R01 AG062574NINDS NIH HHS R01 NS097783
6 · The paper itself

Abstract

introductionDopamine medication withdrawal in Parkinson's disease (PD) is commonly employed in clinical practice and can be required for participation in research studies. When asked to withdraw from medications, participants often enquire as to what symptoms they should expect.

objectivesThis study sought to improve the informed consent process by identifying patient-reported symptoms when dopamine treatment is withheld. We also sought to provide clinical guidance regarding the extent of these symptoms and consider participant willingness to undergo these assessments.

methodsParticipants were recruited from community-based PD programs and support groups in Nashville, Tennessee, USA. A patient-based questionnaire determined the frequency and severity of motor and nonmotor symptoms. The questionnaire also assessed whether patients would be willing to abstain from medication at a future date and under what circumstances.

resultsA total of 31/90 participants reported willingness to withdraw from dopaminergic medications for clinical or research purposes. Tremor, walking, and balance were the most common motor symptoms that worsened during this time. Sleep dysfunction, constipation, and tremor were noted as the most severe symptoms. Of note, 10% of participants indicated that they would not be willing to go off medications again, suggesting that a minority of patients find this to be most discomforting. When prompted for a reason why participants would be willing to come off of their medications again, "for clinical purposes" was selected the most.

conclusionsStudy teams should list these symptoms in the applications to their institutional review board and in the informed consent to provide guidance for participants.

Indexed as

Parkinson DiseaseDopamineHumansInformed ConsentSurveys and QuestionnairesTremorDopamine

Identifiers

PMID33914276
PMCPMC8721843

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.